Olema Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	18.82	24.71	20.39	7.82	0.4	0.39
Research & Development	86.14	82.27	51.1	13.7	3.92	1.69
Operating Expenses	104.96	106.99	71.49	21.53	4.32	2.08
Operating Income	-104.96	-106.99	-71.49	-21.53	-4.32	-2.08
Interest Expense / Income	0	0	0	0.65	0	0.03
Other Expense / Income	-8.31	-2.2	-0.4	-0.06	-0.01	0.09
Pretax Income	-96.66	-104.79	-71.1	-22.12	-4.32	-2.2
Net Income	-96.66	-104.79	-71.1	-22.12	-4.32	-2.2
Preferred Dividends	0	0	0	1.87	0	0
Net Income Common	-96.66	-104.79	-71.1	-23.99	-4.32	-2.2
Shares Outstanding (Basic)	45	40	40	7	3	3
Shares Outstanding (Diluted)	45	40	40	7	3	3
Shares Change	13.13%	1.19%	462.91%	170.75%	2.80%	-
EPS (Basic)	-2.14	-2.62	-1.80	-3.42	-1.66	-0.87
EPS (Diluted)	-2.14	-2.62	-1.80	-3.42	-1.66	-0.87
Free Cash Flow	-83.71	-82.43	-52.27	-19.92	-3.08	-2.18
Free Cash Flow Per Share	-1.85	-2.06	-1.32	-2.84	-1.19	-0.86
EBITDA	-94.98	-103.13	-69.71	-21.46	-4.31	-2.16
Depreciation & Amortization	1.67	1.66	1.39	0.01	0.01	0.01
EBIT	-96.66	-104.79	-71.1	-21.47	-4.32	-2.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).